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INTRODUCTION
Transthyretin familial amyloid polyneuropathy (TTR-FAP) is the most common phenotypic presentation of the TTR amyloidoses, a group of fatal autosomal dominant disorders of variable penetrance caused by mutated TTR that facilitates dissociation of TTR tetramers into amyloidogenic misfolded TTR and subsequent assembly into TTR amyloid which deposits into various organs [1] . The particularly affected anatomical structures are the peripheral and autonomic nerves, heart, gastrointestinal tract, kidneys, eyes, and connective tissue of the carpal ligament [1, 2] . Worldwide, [100 point mutations of the TTR gene located on chromosome 18q12.1 have been described, nearly all of which can lead to amyloidosis [3] . The vast majority of TTR-FAP cases (85%) are associated with replacement of valine by methionine at position 30 of the protein (Val30Met) [1, 3, 4] . The hallmark of TTR-FAP is neurodegeneration of sensory, motor, and autonomic nerve fibers [1] . Gastrointestinal features are prominent in most cases, vary considerably in type and severity both within and between TTR mutations, and may present before the onset of peripheral polyneuropathy [5] . Weight loss, nausea, and alternating bouts of constipation and diarrhea are common during early-stage disease, while malabsorption, severe chronic diarrhea, and cachexia often occur during late-stage disease [5] [6] [7] [8] [9] [10] . Severe malnutrition and opportunistic infections lead to death in these late-stage patients [10, 11] .
Body functional capacity, and survival after liver transplant [11, 12] . Furthermore, mBMI reports on hepatic synthetic capacity, and on neurogenic and absorptive gastrointestinal functions. As such, mBMI should be considered an integrative physiologic indicator for patients with TTR-FAP.
Tafamidis is a once-daily, orally bioavailable, pharmacological chaperone and kinetic stabilizer of TTR approved for the treatment of adult patients with TTR-FAP in several countries [13, 14] . Tafamidis binds with high affinity and selectivity to patient-derived wild-type TTR and to most amyloidogenic TTR variants capable of forming tetramers, including the Val30Met TTR variant [13] . In a randomized, placebocontrolled trial (Fx-005, NCT00409175) of patients with Val30Met TTR-FAP [15] , tafamidis was well tolerated and associated with slowing the progression of peripheral neurologic impairment and was better at preserving quality of life versus placebo [15] .
One of the other multiple outcome measures used to evaluate the efficacy of tafamidis was nutritional status at 18 months, which improved in the tafamidis group but worsened in the placebo group [15] . Furthermore, the deterioration in mBMI observed among placebo-treated patients in this study was reversed by tafamidis during this study's
12-month open-label extension phase [16] .
Given the prominent role that nutrition plays in TTR-FAP progression, the objective of the present post hoc analysis was to present a more detailed account of the effects of tafamidis on nutritional status as measured by mBMI and its components in patients with TTR-FAP who participated in these clinical trials.
METHODS

Patients and Study Designs
The full methodologies of the two international multicenter trials (ClinicalTrials.gov: Fx-005, NCT00409175; Fx-006, NCT00791492) have been published previously [15, 16] [17] . Informed consent was obtained from all patients for being included in the study.
Clinical Assessment
In both studies, mBMI was calculated as the product of the BMI and serum albumin concentration. Height, weight, and albumin were measured during the baseline visit, and weight and serum albumin were measured during each follow-up visit (every 6 months during treatment) up to and including the month 30 end-of-treatment visit.
Analysis Populations
A longitudinal mBMI analysis was conducted on the intent-to-treat (ITT) population of the extension study, defined as those patients who completed the randomized, controlled study per-protocol, enrolled in the extension phase, and received at least one dose of study medication without an interruption of [2 months between the two studies.
Statistical Analysis
All efficacy data analyses were performed using descriptive statistics (mean ± standard deviation for baseline parameters and least squares mean ± standard error for ontreatment comparisons) using SAS BMI strata at each visit were analyzed using repeated measures mixed models with change from baseline as the dependent variable, and treatment, baseline BMI strata, and treatmentby-BMI strata as fixed effects.
RESULTS
Patient Disposition
The flow of patients through the randomized, controlled study and its extension phase has been described previously and is summarized in Fig. 1 This between-group difference widened slightly when patients entered the extension phase but statistical significance was lost because the sample size had decreased relative (Fig. 2a) . At the conclusion of the open-label extension study, the patients in the placebo treatment group had a change from baseline increase in mBMI of 28 ± 19 kg/m 2 g/l while the tafamidis patients had an mBMI increase of 16 ± 18 kg/m 2 g/l, there being no statistically significant difference between the two groups (P = 0.64). mBMI changes from baseline to month 18 were highly comparable across the study centers, with the tafamidis groups having a mean gain in mBMI at every study center, whereas the placebo groups had a The reversal of mean mBMI decrements observed after patients switched from placebo to tafamidis in the extension study manifested because of improvements in both components of the mBMI (BMI and serum albumin level) during the tafamidis treatment phase (Fig. 2b,  c) .
To examine the effect of initial BMI on changes from baseline in BMI, the patients were divided into three groups based on baseline BMI: underweight (BMI \20 kg/m The patients summarized in this analysis are only those who continued into the open-label extension (i.e., within 2 months of completing the randomized trial) and received at least one dose of tafamidis. While selection bias may have been introduced into the ITT population of the extension study due to loss of the randomization process, the authors believe that the degree of selection bias is minor as the tafamidis and placebo groups were matched regarding demographics and clinical characteristics at baseline, and most patients discontinued the randomized, controlled trial to obtain liver transplants. It should be further noted that the studies were short relative to the duration of disease. Nevertheless, our findings that tafamidis was associated with maintaining or improving mBMI over a 2.5-year period in TTR-FAP, tafamidis was associated with negligible efficacy on neurological function and disability [22] . It could be argued that the mBMI improvement observed is related to an increased appetite and not related to tafamidis efficacy; however, the finding of a more pronounced effect on patients presenting with low mBMIs makes such an assumption less convincing. In addition, the nonsteroidal antiinflammatory drug (NSAID) diflunisal, which also showed efficacy as a disease modifying agent in a recent controlled trial [20] , only had a modest impact on mBMI. Nausea and dyspepsia are common adverse effects of NSAIDs [21] , which may explain the more modest response in mBMI among diflunisal recipients in the trial.
In addition to the utility of mBMI as a postsurgical outcome predictor [12, 23] , this simple and easy to use internal medicine tool can be a reliable measure reflecting the clinical course of TTR-FAP and treatment response.
Improvements in mBMI coincide with improvements in neurologic function and quality of life [15, 24] , while deteriorating mBMI is associated with disease progression [11] . In Portuguese patients with Val30Met TTR-FAP, weight loss preceded neurological and gastrointestinal symptoms in a substantial proportion of the patients [7] . Although data from prospective, observational studies revealed that patients with an mBMI \700 kg/m 2 g/l have lower survival rates than patients with higher mBMIs after liver transplant [12, 23] , there is no absolute threshold value identifying patients with a normal mBMI from those without. In a cross-sectional observational study, healthy volunteers had a mean mBMI TTR-FAP [9] ; it is reasonable to suggest that the BMI component of mBMI would be negatively impacted by the classic early-stage symptoms of gastroparesis (i.e., nausea, vomiting, and early satiety) [26] . The mechanisms by which amyloidogenesis causes gastric retention have yet to be elucidated but this problem is evident in patients with normal sympathetic and parasympathetic activity, and only weakly correlated with autonomic neuropathy [9] . 
